---
title: "Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Guidelines questions"
description: "Guidelines questions on Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does the CDC recommend Shingrix for adults 50 and older? Does the CDC recommend Shingrix for immunocompromised adults 19 and older? Shingrix and diabetes: what do ADA and AACE guidelines recommend? Shingrix and COPD: what does the GOLD report recommend? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Guidelines questions

Manufacturer: GlaxoSmithKline Biologicals; GlaxoSmithKline  
Prescribing information: [Shingrix](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF)

Guidelines questions that apply to every indication of Shingrix are on [Shingrix (Zoster Vaccine Recombinant, Adjuvanted), all indications: Guidelines](https://www.evicenter.com/medical-information/shingrix/guidelines).

## Guidelines

<a id="shingrix-cdc-recommendation-50-and-older"></a>

### Does the CDC recommend Shingrix for adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “CDC recommends 2 doses of SHINGRIX to prevent shingles and related complications in adults 
> aged ≥50 years<sup>1</sup>*”

Source: [SHINGRIX: shingles-vaccine-recommendations.pdf, page 1, captured 2026-11-14](https://shingrixhcp.com/content/dam/brs-pharma-us/shingrix-hcp/en_us/pdf/shingles-vaccine-recommendations.pdf#page=1)

> “*Two doses of SHINGRIX separated by 2-6 months. However, for persons who are or will be immunodeficient or 
> immunosuppressed and who would benefit from completing the series in a shorter period, the second dose can be 
> administered 1-2 months after the first.<sup>1</sup>”

Source: [SHINGRIX: shingles-vaccine-recommendations.pdf, page 1, captured 2026-11-14](https://shingrixhcp.com/content/dam/brs-pharma-us/shingrix-hcp/en_us/pdf/shingles-vaccine-recommendations.pdf#page=1)

> “SHINGRIX is not indicated for the prevention of herpes zoster-related complications.<sup>2</sup>”

Source: [SHINGRIX: shingles-vaccine-recommendations.pdf, page 1, captured 2026-11-14](https://shingrixhcp.com/content/dam/brs-pharma-us/shingrix-hcp/en_us/pdf/shingles-vaccine-recommendations.pdf#page=1)

Note: The recommendation is as stated in the manufacturer's Shingles Vaccine Recommendations guide (dated April 2026), which cites the CDC shingles vaccine recommendations web page accessed May 31, 2025.

<a id="shingrix-cdc-recommendation-immunocompromised"></a>

### Does the CDC recommend Shingrix for immunocompromised adults 19 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

> “2 doses of SHINGRIX for the prevention of shingles (herpes zoster) and related complications in adults 19 years of age and older who are or will be immunodeficient or immunosuppressed because of disease or therapy.<sup>1,*</sup>”

Source: [SHINGRIX: CDC Recommendations, captured 2026-11-14](https://shingrixhcp.com/home-ic/who-to-vaccinate/cdc-recommendations/#:~:text=2%20doses%20of%20SHINGRIX%20for,immunosuppressed%20because%20of%20disease%20or)

> “*Recommended for 19 years of age and older to align with the age range in the adult immunization schedule.<sup>1</sup>”

Source: [SHINGRIX: CDC Recommendations, captured 2026-11-14](https://shingrixhcp.com/home-ic/who-to-vaccinate/cdc-recommendations/#:~:text=%2ARecommended%20for%2019%20years%20of,range%20in%20the%20adult%20immunization)

> “SHINGRIX is not indicated for the prevention of herpes zoster-related complications<sup>2</sup>”

Source: [SHINGRIX: CDC Recommendations, captured 2026-11-14](https://shingrixhcp.com/home-ic/who-to-vaccinate/cdc-recommendations/#:~:text=SHINGRIX%20is%20not%20indicated%20for%20the%20prevention%20of%20herpes%20zoster%2Drelated)

Note: The CDC Recommendations page of the immunocompromised section of the Shingrix HCP site presents this recommendation under the heading "CDC Recommends:" and cites the 2022 ACIP recommendations (MMWR). The CDC recommendation covers adults 19 and older; the Prescribing Information indication covers adults 18 and older.

<a id="shingrix-diabetes-guidelines"></a>

### Shingrix and diabetes: what do ADA and AACE guidelines recommend?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Healthcare providers should routinely recommend vaccinations for adults with diabetes as 
> indicated by age. This includes zoster vaccination for adults ≥50 years of age.<sup>3</sup>”

Source: [SHINGRIX: shingles-vaccine-recommendations.pdf, page 1, captured 2026-11-14](https://shingrixhcp.com/content/dam/brs-pharma-us/shingrix-hcp/en_us/pdf/shingles-vaccine-recommendations.pdf#page=1)

> “RZV is recommended for adults aged ≥50 years for protection against shingles, 
> according to the CDC/ACIP vaccination schedule<sup>4</sup>”

Source: [SHINGRIX: shingles-vaccine-recommendations.pdf, page 2, captured 2026-11-14](https://shingrixhcp.com/content/dam/brs-pharma-us/shingrix-hcp/en_us/pdf/shingles-vaccine-recommendations.pdf#page=2)

Note: As presented in the manufacturer's Shingles Vaccine Recommendations guide (April 2026): the ADA statement concerns zoster vaccination and the AACE statement concerns recombinant zoster vaccine (RZV); the guide cites the ADA Standards of Care in Diabetes 2025 and the AACE 2022 clinical practice guideline.

<a id="shingrix-copd-guidelines"></a>

### Shingrix and COPD: what does the GOLD report recommend?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “People with COPD should receive all recommended vaccinations in line with  
> relevant local guidelines. 
> For people with stable COPD:
> •	Zoster vaccine to protect against shingles for people with COPD aged  
> >50 years, as recommended by the CDC<sup>5</sup>”

Source: [SHINGRIX: shingles-vaccine-recommendations.pdf, page 2, captured 2026-11-14](https://shingrixhcp.com/content/dam/brs-pharma-us/shingrix-hcp/en_us/pdf/shingles-vaccine-recommendations.pdf#page=2)

Note: As presented in the manufacturer's Shingles Vaccine Recommendations guide (April 2026): the GOLD statement concerns zoster vaccination in general; the guide cites the 2025 GOLD report.

## Related pages
- [Medical information: Shingrix (Zoster Vaccine Recombinant, Adjuvanted): Herpes zoster prevention](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention)
- [Indication](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/safety)
- [Specific populations](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/access-and-coverage)
